Endocrinology

An oral antibiotic for drug-resistant UTIs, a long-awaited therapy for congenital adrenal hyperplasia, and more.

In preliminary findings of the phase 2b QUALITY trial, 32% of weight loss in the semaglutide group was from lean mass reduction vs 9.4% in the combined semagutide/enobosarm group.

Weekly subcutaneous injections of amycretin featured a safety profile similar to other incretin-based drugs, according to new topline results.

Incretin-mimetics may have even broader application against disease than scientists can predict, but the risks are real, too, according to a study of 2 million.

The properties of ASC30 may allow the small molecule GLP-1 RA to be formulated as a monthly injection and daily oral tablet, Ascletis said.

Your daily dose of the clinical news you may have missed.

The 20.7% weight loss with the high-dose of semaglutide bested the mean reduction of 17.5% seen with semaglutide 2.4 mg, according to Novo Nordisk.

Your daily dose of the clinical news you may have missed.

"Glucocorticoid therapy in classic congenital adrenal hyperplasia: traditional and new treatment paradigms," offers an in-depth look at the disorder and promising therapies.

Shagun Bindlish, MD, board member of the American Diabetes Association, details available options for treating venous disease in patients with obesity.

More than half of study participants receiving the dual incretin agonist had weight loss of 20% or greater, with no evidence of a plateau and only mild AEs.

Atumelnant treatment resulted in statistically significant reductions in serum androstenedione and 17-OHP as well as notable improvements in CAH symptoms.

Elinzanetant produced a statistically significant reduction in frequency of treatment-related vasomotor symptoms as early as week 1 and in severity at weeks 4 and 12.

In an unusual step, the agency's draft guidance recommends the efficacy benchmark for drug approval while emphasizing clinical trial structure and cohort development.

Donna Ryan, MD, discusses the most significant clinical trials published this year in the field of obesity medicine.

Donna Ryan, MD, highlights exciting advancements in weight loss and metabolic treatments, particularly involving GLP-1 RAs and related therapies.

In November 2024, an FDA advisory committee said the benefits of sotagliflozin do not outweigh the risks in adults with type 1 diabetes and chronic kidney disease.

The future of obesity medicine is filled with promise as GLP-1 RAs and other peptides continue to demonstrate pluripotency in metabolic disease.

The FDA has approved the first generic once-daily GLP-1 injection for the improvement of glycemic control for type 2 diabetes in patients 10 years and up.

The first in class CRF-1 receptor antagonist allows people with CAH to reduce glucocorticoid doses while androgen levels are maintained or improved.

The 22.7% weight loss at 68 weeks places CagriSema essentially on par with, not superior to, competing antiobesity drugs including Lilly's tirzepatide.

The lead investigator of the largest clinical trial program in people with CAH discusses the condition, its burden, and the novel drug just approved that will change lives.

Auchus details findings from the unique study of the CRF-1 antagonist crinecerfont, the first new therapy for CAH approved in 70 years.

Crinecerfont approval makes available the first new treatment for the life-altering endocrine disorder in more than 70 years, according to Neurocrine Biosciences.

Your daily dose of the clinical news you may have missed.